Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Nouscom AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nouscom Receives Approval to Begin Phase 1b Trials of NOUS-PEV, a Novel Personalized Cancer Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Nouscom AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nouscom to Present Full Phase 1 Data of NOUS-209, an 'off-the-shelf' Neoantigen Cancer Immunotherapy for the Treatment of dMMR\/MSI-H Solid Tumors, at ASCO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Nouscom AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nouscom Announces Positive Full Phase 1 Data of NOUS-209, an 'off-the-shelf' Neoantigen Cancer Immunotherapy for the Treatment of dMMR\/MSI-H Solid Tumors, at ASCO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Nouscom AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nouscom Announces Leading Publication Revealing an Immune Mechanism of Action Driving Anti-tumor Activity of Adenovirus Vectored Vaccines and Anti-PD1 Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Nouscom AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nouscom Announces First Patient Dosed in Phase 2 Randomized Trial with NOUS-209, an 'off-the shelf' Neoantigen Cancer Immunotherapy in dMMR\/MSI-High Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Nouscom AG","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nouscom Announces Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate NOUS-209 in combination with KEYTRUDA\u00ae (pembrolizumab) in a Phase 2 Randomized Trials in dMMR\/MSI-High Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Nouscom AG","sponsor":"ProBioGen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nouscom Reaches Clinical Phase II Using ProBioGen\u2019s AGE1.CR.pIX\u00ae Production Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Nouscom AG","sponsor":"Andera Partners","pharmaFlowCategory":"D","amount":"$72.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nouscom Raises \u20ac67.5 million ($72 million) in Oversubscribed Series C Financing Round","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Nouscom AG","sponsor":"Angelini Ventures","pharmaFlowCategory":"D","amount":"$82.1 million","upfrontCash":"Undisclosed","newsHeadline":"Angelini Ventures Invests into Extended \u20ac75.8 million ($82 million) Series C financing Round for Nouscom, a Clinical Stage Immuno-Oncology Company Developing Off-The-Shelf and Personalized Cancer Vaccines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by Nouscom AG

    Menu

    Nouscom AG

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Nouscom AG

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Angelini Ventures Invests into Extended €75.8 million ($82 million) Series C financing Round for Nouscom, a Clinical Stage Immuno-Oncology Company Developing Off-The-Shel...

              Details:

              The net proceeds will enable Nouscom to continue advancing and expanding its wholly owned clinical pipeline including readout from its ongoing randomized Phase 2 clinical trial for NOUS-209, an off-the-shelf cancer vaccine for dMMR/MSI Metastatic Colorectal Cancer.

              Lead Product(s): NOUS-209,Pembrolizumab

              Therapeutic Area: Oncology Product Name: NOUS-209

              Highest Development Status: Phase I/ Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: Angelini Ventures

              Deal Size: $82.1 million Upfront Cash: Undisclosed

              Deal Type: Series C Financing March 21, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Nouscom AG

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Nouscom Raises €67.5 million ($72 million) in Oversubscribed Series C Financing Round

              Details:

              The proceeds will be used to continue advancing and expanding Nouscom’s wholly owned clinical pipeline, including NOUS-209 (GAd20-209-FSP), an off-the-shelf cancer vaccine targeting 209 shared neoantigens.

              Lead Product(s): GAd20-209-FSP,MVA-209-FSP,Pembrolizumab

              Therapeutic Area: Oncology Product Name: NOUS-209

              Highest Development Status: Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: Andera Partners

              Deal Size: $72.0 million Upfront Cash: Undisclosed

              Deal Type: Series C Financing November 14, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Nouscom AG

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Nouscom Reaches Clinical Phase II Using ProBioGen’s AGE1.CR.pIX® Production Platform

              Details:

              Nous-209 is based on a heterologous prime/boost regimen composed of the Great Ape Adenovirus GAd20-209-FSP used for priming and Modified Vaccinia virus Ankara MVA-209-FSP used for boosting.

              Lead Product(s): GAd20-209-FSP,MVA-209-FSP,Pembrolizumab

              Therapeutic Area: Oncology Product Name: Nous-209

              Highest Development Status: Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: ProBioGen

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 04, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Nouscom AG

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Nouscom Announces Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate NOUS-209 in combination with KEYTRUDA® (pembrolizumab) in a Phase 2 Randomized Tri...

              Details:

              NOUS-209 (GAd20-209-FSP) is an off-the-shelf cancer immunotherapy for MSI-H tumors. MSI-H tumors are characterized by a defective DNA mismatch repair system, which generates highly immunogenic neoantigens called frame shift peptides that are not present in healthy tissue.

              Lead Product(s): GAd20-209-FSP,MVA-209-FSP,Pembrolizumab

              Therapeutic Area: Oncology Product Name: NOUS-209

              Highest Development Status: Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: MSD Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration January 05, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Nouscom AG

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Nouscom Announces First Patient Dosed in Phase 2 Randomized Trial with NOUS-209, an 'off-the shelf' Neoantigen Cancer Immunotherapy in dMMR/MSI-High Metastatic Colorectal C...

              Details:

              NOUS-209 (GAd-209-FSP) is an off-the-shelf cancer immunotherapy for Microsatellite Instable High (MSI-H) tumors, generates highly immunogenic neoantigens called frame shift peptides (FSP) that are not present in healthy tissue.

              Lead Product(s): GAd-209-FSP,Pembrolizumab

              Therapeutic Area: Oncology Product Name: NOUS-209

              Highest Development Status: Phase I/ Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 15, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Nouscom AG

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Nouscom Announces Leading Publication Revealing an Immune Mechanism of Action Driving Anti-tumor Activity of Adenovirus Vectored Vaccines and Anti-PD1 Immunotherapy

              Details:

              This mechanism was characterized in preclinical model of colorectal cancer and confirmed in Phase 1b trial in gastrointestinal patients with (MSI-H) tumors who saw durable clinical responses when treated with NOUS-209(GAd-209-FSP) in combination with anti-PD1.

              Lead Product(s): GAd-209-FSP,Pembrolizumab

              Therapeutic Area: Oncology Product Name: NOUS-209

              Highest Development Status: Phase I/ Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 11, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Nouscom AG

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Nouscom Announces Positive Full Phase 1 Data of NOUS-209, an 'off-the-shelf' Neoantigen Cancer Immunotherapy for the Treatment of dMMR/MSI-H Solid Tumors, at ASCO 2022

              Details:

              NOUS-209 (GAd-209-FSP), is an off-the-shelf cancer vaccine targeting 209 shared neoantigens, in combination with anti-PD-1 checkpoint inhibitor pembrolizumab, for the treatment of deficiency in Mismatch Repair/Microsatellite Instable HigH unresectable or metastatic tumors.

              Lead Product(s): GAd-209-FSP,Pembrolizumab

              Therapeutic Area: Oncology Product Name: NOUS-209

              Highest Development Status: Phase I/ Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 06, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Nouscom AG

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Nouscom to Present Full Phase 1 Data of NOUS-209, an 'off-the-shelf' Neoantigen Cancer Immunotherapy for the Treatment of dMMR/MSI-H Solid Tumors, at ASCO 2022

              Details:

              NOUS-209 (GAd-209-FSP) is an off-the-shelf immunotherapy for Microsatellite Instable High (MSI-H) tumors. MSI-H tumors are characterized by a defective DNA mismatch repair system, which generates highly immunogenic frame shift peptides that are not found on healthy tissue.

              Lead Product(s): GAd-209-FSP,Pembrolizumab

              Therapeutic Area: Oncology Product Name: NOUS-209

              Highest Development Status: Phase I/ Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 27, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Nouscom AG

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Nouscom Receives Approval to Begin Phase 1b Trials of NOUS-PEV, a Novel Personalized Cancer Immunotherapy

              Details:

              NOUS-PEV will be investigated in the study as a potential treatment for patients with either locally advanced 1L melanoma or 1L non-small cell lung cancer (NSCLC).

              Lead Product(s): NOUS-PEV

              Therapeutic Area: Oncology Product Name: NOUS-PEV

              Highest Development Status: Preclinical Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 11, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY